Claims for Patent: 8,546,434

Summary for Patent: 8,546,434

Title:	Triazole compounds as KSP inhibitors
Abstract:	The present invention provides triazole compounds of Formula I: ##STR00001## as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.
Inventor(s):	Abrams; Tinya (Richmond, CA), Barsanti; Paul (Pleasant Hill, CA), Ding; Yu (Union City, CA), Duhl; David (Oakland, CA), Han; Wooseok (San Ramon, CA), Hu; Cheng (Menlo Park, CA), Pan; Yue (Albany, CA)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/085,746
Patent Claims:	1. A compound of Formula I ##STR00099## wherein: R.sup.1 is selected from C.sub.1-6 alkoxy-C.sub.1-4-alkyl; R.sup.2 is selected from H, and C.sub.1-6 straight chain alkyl; R.sup.3 represents --(CH.sub.2).sub.0-3 substituted or unsubstituted pyrrolidinyl; R.sup.4 is selected from --C(O)--CH.sub.2OH, --C(O)-tetrahydrofuranyl, --C(O)--CH(CH.sub.3)--OH, --C(O)-unsubstituted morpholinyl, and --C(O)-morpholinyl substituted with up to three alkyl groups; R.sup.5 is selected from substituted or unsubstituted benzyl, wherein the substituents are selected from Cl, F, Br, and I; and R.sup.6 is selected from phenyl substituted with up to three halogen atoms. 2. A compound of claim 1, wherein: R.sup.1 is selected from C.sub.1-6alkoxy-C.sub.1-4-alkyl; R.sup.2 represents H; R.sup.3 represents --(CH.sub.2).sub.1-3-substituted pyrrolidinyl; R.sup.4 is selected from --C(O)-tetrahydrofuranyl, --C(O)--CH(CH.sub.3)--OH, --C(O)-morpholinyl substituted with up to three alkyl groups; R.sup.5 represents benzyl, or benzyl substituted with up to two fluoro atoms; and R.sup.6 is selected from phenyl substituted with up to two halogen atoms. 3. A compound of claim 1, wherein: R.sup.1 represents C.sub.1-6 alkoxy-C.sub.1-4-alkyl; R.sup.3 represents --(CH.sub.2)-fluoro-pyrrolidinyl; R.sup.4 is selected from --C(O)-tetrahydrofuranyl, --C(O)--CH(CH.sub.3)--OH, --C(O)-2,6-dimethyl morpholinyl; R.sup.5 represents benzyl, or benzyl substituted with one fluoro atom; and R.sup.6 is selected from phenyl substituted with up to two fluoro atoms. 4. A compound of claim 2, wherein: R.sup.3 represents --(CH.sub.2).sub.1-3-fluoro-pyrrolidinyl; and R.sup.4 represents --C(O)-2-tetrahydrofuranyl, --C(O) --CH(CH.sub.3)--OH, or --C(O)-2,6-dimethyl morpholinyl. 5. A compound of claim 4, wherein: R.sup.3 represents ##STR00100## R.sup.4 is selected from --C(O)--CH(CH.sub.3)--OH, and ##STR00101## 6. A compound of claim 5, wherein: R.sup.5 represents ##STR00102## R.sup.6 is ##STR00103## 7. A compound according to claim 1, wherein R.sup.4 is selected from: ##STR00104## 8. A compound selected from ##STR00105## ##STR00106## and the pharmaceutically acceptable salts of these compounds. 9. A compound of Formula (II): ##STR00107## wherein, R.sup.1 is selected from C.sub.1-6 alkoxy-C.sub.1-4-alkyl; R.sup.3 represents --(CH.sub.2).sub.0-3-substituted or unsubstituted pyrrolidinyl or C.sub.3-5 alkyl substituted with up to three groups selected from amino and halo; R.sup.4 is selected from --C(O)--CH.sub.2--OH, --C(O)-tetrahydrofuranyl, --C(O)--CH(CH.sub.3)--OH, --C(O)-unsubstituted morpholinyl, and --C(O)-morpholinyl substituted with up to three alkyl groups; R.sup.5 is selected from substituted or unsubstituted benzyl, wherein the substituents are selected from Cl, F, Br, and I; and R.sup.6 is selected from phenyl substituted with up to three halogen atoms. 10. The compound of claim 9, wherein: R.sup.l is selected from C.sub.1-6 alkoxy-C.sub.1-4-alkyl; R.sup.3 represents --(CH.sub.2).sub.0-3-substituted pyrrolidinyl or --CH.sub.2--CH.sub.2--CH(NH.sub.2)--CH.sub.2F; R.sup.4 is selected from --C(O)--CH.sub.2OH, --C(O)-tetrahydrofuranyl, --C(O)--CH(CH.sub.3)--OH, --C(O)-unsubstituted morpholinyl, and --C(O)-morpholinyl substituted with up to three alkyl groups; R.sup.5 is selected from substituted or unsubstituted benzyl, wherein the substituents are selected from Cl, F, Br, and I; and R.sup.6 is selected from phenyl substituted with up to three halogen atoms. 11. The compound of claim 9, wherein R.sup.1 is methoxy-substituted C.sub.1-4 alkyl. 12. The compound of claim 11, wherein R.sup.1 is 2-methoxy-2-propyl. 13. A compound of claim 9, wherein: R.sup.3 represents --(CH.sub.2).sub.1-3-substituted pyrrolidinyl or --CH.sub.2--CH.sub.2--CH(NH.sub.2)--CH.sub.2F; R.sup.4 is selected from --C(O)-tetrahydrofuranyl, --C(O)--CH(CH.sub.3)--OH, and --C(O)-morpholinyl substituted with up to three alkyl groups; R.sup.5 represents benzyl, or benzyl substituted with up to two fluoro atoms; and R.sup.6 is selected from phenyl substituted with up to two halogen atoms. 14. A compound of claim 13, wherein: R.sup.1 represents 2-methoxy-2-propyl; R.sup.3 represents --(CH.sub.2)-fluoro-pyrrolidinyl or --CH.sub.2--CH.sub.2--CH(NH.sub.2)--CH.sub.2F; R.sup.4 is selected from --C(O)-tetrahydrofuranyl, --C(O)--CH(CH.sub.3)--OH, and --C(O)-2,6-dimethyl morpholinyl; R.sup.5 represents benzyl, or benzyl substituted with one fluoro atom; and R.sup.6 is selected from phenyl substituted with up to two fluoro atoms. 15. A compound of claim 14, wherein: R.sup.3 represents --(CH.sub.2).sub.1-3-fluoro-pyrrolidinyl or --CH.sub.2--CH.sub.2--CH(NH.sub.2)--CH.sub.2F; and R.sup.4 represents --C(O)-2-tetrahydrofuranyl, --C(O)--CH(CH.sub.3)--OH, and --C(O)-2,6-dimethyl morpholinyl. 16. A compound of claim 15, wherein: R.sup.3 represents ##STR00108## R.sup.4 is selected from --C(O)--CH(CH.sub.3)--OH, ##STR00109## R.sup.5 is ##STR00110## R.sup.6 is ##STR00111## 17. The compound of claim 9, wherein R.sup.4 is selected from: ##STR00112## 18. The compound of claim 9, wherein the compound is selected from the group consisting of: ##STR00113## ##STR00114## and the pharmaceutically acceptable salts thereof. 19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable carrier. 20. The composition of claim 19 further comprising at least one additional agent for the treatment of cancer, wherein the additional agent for the treatment of cancer is selected from the group consisting of irinotecan, topotecan, gemcitabine, imatinib, trastuzumab, 5-fluorouracil, leucovorin, carboplatin, cisplatin, docetaxel, paclitaxel, tezacitabine, cyclophosphamide, vinca alkaloids, anthracyclines, rituximab, and trastuzumab. 21. A method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of claim 1 wherein the disorder is cancer selected from the group consisting of lung and bronchus; prostate; breast; pancreas; colon and rectum; thyroid; stomach; liver and intrahepatic bile duct; kidney and renal pelvis; urinary bladder; uterine corpus; uterine cervix; ovary; multiple myeloma; esophagus; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; oral cavity and pharynx; larynx; small intestine; non-Hodgkin lymphoma; melanoma; and villous colon adenoma. 22. A method for inhibiting KSP in a mammalian patient, wherein said method comprises administering to the patient an effective KSP-inhibiting amount of a compound of claim 1.

Details for Patent 8,546,434

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-03-29
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2039-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-03-29